Alpha Cognition Inc. Net Income (Loss) Attributable to Parent, Diluted
Alpha Cognition Inc. (ACOG) reported Net Income (Loss) Attributable to Parent, Diluted of -$8.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-08-13
- Alpha Cognition Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was -$8.79M.
- Alpha Cognition Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was -$13.20M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$8.79M 10-Q · filed 2026-08-13 | -$15.63M 10-Q · filed 2026-08-13 |
| 2025-06-30 | -$13.20M 10-Q · filed 2026-08-13 | -$14.92M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |